Overview
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions. It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
Background
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions. It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
Indication
Otic solutions are indicated for infections of the external auditory canal caused by susceptible organisms and with inflammation. Hydrocortisone tablets are indicated for certain endocrine, rheumatic, collagen, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, gastrointestinal, and other conditions. A hydrocortisone enema is indicated for ulcerative colitis, a topical ointment with antibiotics is indicated for corticosteroid responsive dermatoses with infections, and a topical cream with acyclovir is indicated to treat cold sores. Oral granules of hydrocortisone are used as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 years of age.
Associated Conditions
- Acute Gouty Arthritis
- Acute Leukemia
- Acute Otitis Externa
- Adrenal Insufficiency
- Allergic Conjunctivitis (AC)
- Allergic Rhinitis (AR)
- Allergic corneal marginal ulcers
- Ankylosing Spondylitis (AS)
- Aspiration Pneumonitis
- Asthma
- Atopic Dermatitis
- Berylliosis
- Bullous dermatitis herpetiformis
- Chorioretinitis
- Choroiditis
- Congenital Adrenal Hyperplasia (CAH)
- Congenital Hypoplastic Anemia
- Contact Dermatitis
- Crohn's Disease (CD)
- Dermatitis
- Dermatomyositis (DM)
- Dermatosis
- Drug hypersensitivity reaction
- Epicondylitis
- Erythroblastopenia
- Fissure;Anal
- Haemorrhoids
- Herpes Labialis
- Hypercalcemia of Malignancy
- Immune Thrombocytopenia (ITP)
- Infection of the Fenestration Cavity
- Infection of the Mastoidectomy Cavity
- Iridocyclitis
- Iritis
- Itching caused by Hemorrhoids
- Itching of the Anus
- Keratitis
- Leukemias
- Loeffler's syndrome
- Lymphoma
- Lymphomas NEC
- Mycosis Fungoides (MF)
- Ophthalmia, Sympathetic
- Optic Neuritis
- Pain caused by Hemorrhoids
- Pemphigus
- Posterior Uveitis
- Posttraumatic Osteoarthritis
- Primary adrenocortical insufficiency
- Proctitis
- Proteinuria
- Pruritis of the skin
- Psoriatic Arthritis
- Rectal inflammations NEC
- Rheumatic heart disease, unspecified
- Rheumatoid Arthritis
- Rheumatoid Arthritis, Juvenile
- Secondary adrenocortical insufficiency
- Secondary thrombocytopenia
- Serum Sickness
- Severe Seborrheic Dermatitis
- Skin Diseases
- Stevens-Johnson Syndrome
- Synovitis
- Systemic Lupus Erythematosus
- Trichinosis
- Tuberculous Meningitis
- Ulcerative Colitis
- Acquired immune hemolytic anemia
- Acute Bursitis
- Acute Tenosynovitis
- Acute rheumatic carditis
- Anterior eye segment inflammation
- Cryptitis
- Disseminated Pulmonary Tuberculosis (TB)
- Exfoliative erythroderma
- Fulminating Pulmonary Tuberculosis
- Non-suppurative Thyroiditis
- Severe Erythema multiforme
- Severe Psoriasis
- Subacute Bursitis
- Superficial infection of the external auditory canal with inflammation
- Symptomatic Sarcoidosis
- Systemic Dermatomyositis
- Varicella-zoster virus acute retinal necrosis
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2020/09/02 | Not Applicable | Completed | University of Molise | ||
2020/09/02 | Phase 4 | UNKNOWN | Shanghai Jiao Tong University School of Medicine | ||
2020/08/11 | Phase 3 | Completed | Air Force Specialized Hospital, Cairo, Egypt | ||
2020/07/30 | Phase 4 | Completed | |||
2020/07/10 | Not Applicable | Completed | |||
2020/07/02 | N/A | AVAILABLE | |||
2020/06/17 | Early Phase 1 | Completed | |||
2020/04/24 | Phase 3 | Withdrawn | |||
2020/04/16 | Phase 3 | Completed | Scandinavian Critical Care Trials Group | ||
2020/03/27 | Phase 4 | Completed |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Unit Dose Services | 50436-2143 | TOPICAL | 25 mg in 1 g | 7/10/2014 | |
| Crown Laboratories | 0316-0193 | TOPICAL | 25 mg in 1 g | 10/24/2023 | |
| Bryant Ranch Prepack | 63629-8666 | TOPICAL | 25 mg in 1 g | 7/18/2023 | |
| Eton Pharmaceuticals, Inc. | 71863-118 | ORAL | 1 mg in 1 1 | 2/28/2024 | |
| Greenstone LLC | 59762-0074 | ORAL | 10 mg in 1 1 | 1/23/2024 | |
| Mylan Pharmaceuticals Inc. | 59762-0074 | ORAL | 10 mg in 1 1 | 1/23/2024 | |
| E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. | 0168-0146 | TOPICAL | 25 mg in 1 g | 7/10/2014 | |
| Chartwell RX, LLC. | 62135-552 | ORAL | 10 mg in 1 1 | 3/21/2023 | |
| Sandoz Inc | 61314-646 | AURICULAR (OTIC) | 10 mg in 1 mL | 8/13/2020 | |
| Summers Laboratories Inc | 11086-032 | TOPICAL | 0.5 g in 100 g | 10/9/2023 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Hydrocortisone Injection | 国药准字H32020465 | 化学药品 | 注射剂 | 9/9/2020 | |
| Hydrocortisone Injection | 国药准字H62020616 | 化学药品 | 注射剂 | 7/17/2020 | |
| Hydrocortisone Injection | 国药准字H61020712 | 化学药品 | 注射剂 | 11/20/2020 | |
| Hydrocortisone Injection | 国药准字H43021212 | 化学药品 | 注射剂 | 7/11/2022 | |
| Hydrocortisone Injection | 国药准字H20053943 | 化学药品 | 注射剂 | 11/9/2023 | |
| Hydrocortisone Injection | 国药准字H14022507 | 化学药品 | 注射剂 | 4/10/2020 | |
| Hydrocortisone Injection | 国药准字H23020273 | 化学药品 | 注射剂 | 1/14/2024 | |
| Hydrocortisone Injection | 国药准字H62020617 | 化学药品 | 注射剂 | 7/17/2020 | |
| Hydrocortisone Injection | 国药准字H41021790 | 化学药品 | 注射剂 | 8/14/2020 | |
| Hydrocortisone Injection | 国药准字H34020496 | 化学药品 | 注射剂 | 1/7/2021 |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||